Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Queensland Health
Farmers Insurance
US Department of Justice
Harvard Business School
Johnson and Johnson
QuintilesIMS
Fuji
Citi

Generated: April 22, 2018

DrugPatentWatch Database Preview

LIPTRUZET Drug Profile

« Back to Dashboard

Which patents cover Liptruzet, and what generic alternatives are available?

Liptruzet is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-one drug master file entries for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
Summary for LIPTRUZET
Drug patent expirations by year for LIPTRUZET

US Patents and Regulatory Information for LIPTRUZET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for LIPTRUZET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Medtronic
Colorcon
Federal Trade Commission
Moodys
UBS
Boehringer Ingelheim
Covington
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.